Inovio Pharmaceuticals, Inc.
INO
$1.95
$0.073.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.30K | 117.00K | -- | 100.80K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.30K | 117.00K | -- | 100.80K | -- |
| Cost of Revenue | 16.09M | 12.89M | 18.73M | 23.09M | 20.91M |
| Gross Profit | -16.03M | -12.77M | -18.73M | -22.99M | -20.91M |
| SG&A Expenses | 9.03M | 7.60M | 8.61M | 10.21M | 10.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.12M | 20.49M | 27.35M | 33.30M | 31.49M |
| Operating Income | -25.05M | -20.37M | -27.35M | -33.20M | -31.49M |
| Income Before Tax | -19.69M | -19.38M | -25.17M | -32.24M | -30.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.69M | -19.38M | -25.17M | -32.24M | -30.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.69M | -19.38M | -25.17M | -32.24M | -30.47M |
| EBIT | -25.05M | -20.37M | -27.35M | -33.20M | -31.49M |
| EBITDA | -24.68M | -19.95M | -26.93M | -32.71M | -31.06M |
| EPS Basic | -0.51 | -0.65 | -0.89 | -1.19 | -1.31 |
| Normalized Basic EPS | -0.32 | -0.40 | -0.58 | -0.74 | -0.81 |
| EPS Diluted | -0.51 | -0.65 | -0.89 | -1.19 | -1.31 |
| Normalized Diluted EPS | -0.32 | -0.40 | -0.58 | -0.74 | -0.81 |
| Average Basic Shares Outstanding | 38.61M | 29.99M | 28.14M | 27.20M | 23.29M |
| Average Diluted Shares Outstanding | 38.61M | 29.99M | 28.14M | 27.20M | 23.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |